What is Akero Therapeutics, Inc. (AKRO)?

Akero Therapeutics, Inc. (AKRO) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of AKRO?

The current price of AKRO is $54.65. Prices are updated in real time on Stocks360.

What is AKRO's price-to-earnings (PE) ratio?

AKRO's trailing twelve-month PE ratio is -29.54, based on current price and earnings per share data available on Stocks360.

What is AKRO's market capitalization?

AKRO's market capitalization is $4,498,738,105.00, placing it in the mid-cap tier.

Akero Therapeutics, Inc. (AKRO)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$54.65

Market Cap

$4.50B

PE (TTM)

-29.54

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.40

Day Range

$54.52 – $54.65

52-wk Range

$21.34 – $58.40

Avg Volume

N/A

Volume

11.61M

Akero Therapeutics, Inc. (AKRO) is a publicly traded company in the Healthcare sector. Latest price: $54.65. Market cap $4.50B. Trailing PE -29.54. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 6 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-29 · $54.00 2025-12-09 · $54.65 (+1.20%)

Earnings

Most Recent

Nov 7, 2025

EPS $-0.99 vs est. $-0.94

Missed by $0.05

Proprietary Signals

Signal snapshot temporarily unavailable.

About Akero Therapeutics, Inc.

Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-29.54×
P/S (TTM)	0.00×
P/B	4.68×
P/FCF (TTM)	-38.98×
EV / EBITDA	-28.86×
EV / Sales	0.00×
Earnings Yield	-3.39%
Free Cash Flow Yield	-2.57%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$4.32B
Net Income (TTM)	-$152.65M
Free Cash Flow (TTM)	-$113.15M
Net Debt	-$174.87M
Working Capital	$706.88M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-15.33%
Return on Invested Capital	-17.85%